MAOB and serotonin syndrome: Studies performed on both reversible and irreversible compounds have demonstrated in fact that the risk of serotonin syndrome in parkinsonian patients treated with MAO-B inhibitors and antidepressant remains extremely low and did not appear to be greater than that encountered in routine medical therapy [36].